349 related articles for article (PubMed ID: 37022791)
1. Glioblastomas: Hijacking Metabolism to Build a Flexible Shield for Therapy Resistance.
Bailleul J; Vlashi E
Antioxid Redox Signal; 2023 Nov; 39(13-15):957-979. PubMed ID: 37022791
[No Abstract] [Full Text] [Related]
2. Combined acetyl-11-keto-β-boswellic acid and radiation treatment inhibited glioblastoma tumor cells.
Conti S; Vexler A; Edry-Botzer L; Kalich-Philosoph L; Corn BW; Shtraus N; Meir Y; Hagoel L; Shtabsky A; Marmor S; Earon G; Lev-Ari S
PLoS One; 2018; 13(7):e0198627. PubMed ID: 29969452
[TBL] [Abstract][Full Text] [Related]
3. Increased cure rate of glioblastoma using concurrent therapy with radiotherapy and arsenic trioxide.
Ning S; Knox SJ
Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):197-203. PubMed ID: 15337556
[TBL] [Abstract][Full Text] [Related]
4. Molecular Markers of Therapy-Resistant Glioblastoma and Potential Strategy to Combat Resistance.
Nguyen HS; Shabani S; Awad AJ; Kaushal M; Doan N
Int J Mol Sci; 2018 Jun; 19(6):. PubMed ID: 29899215
[TBL] [Abstract][Full Text] [Related]
5. The Importance of Tumor Stem Cells in Glioblastoma Resistance to Therapy.
Mattei V; Santilli F; Martellucci S; Delle Monache S; Fabrizi J; Colapietro A; Angelucci A; Festuccia C
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33917954
[TBL] [Abstract][Full Text] [Related]
6. Antiangiogenic therapies in glioblastoma multiforme.
McNamara MG; Mason WP
Expert Rev Anticancer Ther; 2012 May; 12(5):643-54. PubMed ID: 22594899
[TBL] [Abstract][Full Text] [Related]
7. Theranostic nanoparticles enhance the response of glioblastomas to radiation.
Wu W; Klockow JL; Mohanty S; Ku KS; Aghighi M; Melemenidis S; Chen Z; Li K; Morais GR; Zhao N; Schlegel J; Graves EE; Rao J; Loadman PM; Falconer RA; Mukherjee S; Chin FT; Daldrup-Link HE
Nanotheranostics; 2019; 3(4):299-310. PubMed ID: 31723547
[TBL] [Abstract][Full Text] [Related]
8. Tumor Niches: Perspectives for Targeted Therapies in Glioblastoma.
Srivastava R; Dodda M; Zou H; Li X; Hu B
Antioxid Redox Signal; 2023 Nov; 39(13-15):904-922. PubMed ID: 37166370
[No Abstract] [Full Text] [Related]
9. Evaluation of tyrosine kinase inhibitor combinations for glioblastoma therapy.
Joshi AD; Loilome W; Siu IM; Tyler B; Gallia GL; Riggins GJ
PLoS One; 2012; 7(10):e44372. PubMed ID: 23056179
[TBL] [Abstract][Full Text] [Related]
10. Simultaneous blockade of interacting CK2 and EGFR pathways by tumor-targeting nanobioconjugates increases therapeutic efficacy against glioblastoma multiforme.
Chou ST; Patil R; Galstyan A; Gangalum PR; Cavenee WK; Furnari FB; Ljubimov VA; Chesnokova A; Kramerov AA; Ding H; Falahatian V; Mashouf L; Fox I; Black KL; Holler E; Ljubimov AV; Ljubimova JY
J Control Release; 2016 Dec; 244(Pt A):14-23. PubMed ID: 27825958
[TBL] [Abstract][Full Text] [Related]
11. STAT3 as a Therapeutic Target for Glioblastoma.
Liu Y; Li C; Lin J
Anticancer Agents Med Chem; 2010 Sep; 10(7):512-9. PubMed ID: 20879983
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic targeting of EGFR-activated metabolic pathways in glioblastoma.
Gao Q; Lei T; Ye F
Expert Opin Investig Drugs; 2013 Aug; 22(8):1023-40. PubMed ID: 23731170
[TBL] [Abstract][Full Text] [Related]
13. Safety and Efficacy Assessments to Take Antioxidants in Glioblastoma Therapy: From In Vitro Experiences to Animal and Clinical Studies.
Turkez H; Tozlu OO; Arslan ME; Mardinoglu A
Neurochem Int; 2021 Nov; 150():105168. PubMed ID: 34450218
[TBL] [Abstract][Full Text] [Related]
14. Bioenergetics pathways and therapeutic resistance in gliomas: emerging role of mitochondria.
Griguer CE; Oliva CR
Curr Pharm Des; 2011; 17(23):2421-7. PubMed ID: 21827418
[TBL] [Abstract][Full Text] [Related]
15. Adaptive mitochondrial reprogramming and resistance to PI3K therapy.
Ghosh JC; Siegelin MD; Vaira V; Faversani A; Tavecchio M; Chae YC; Lisanti S; Rampini P; Giroda M; Caino MC; Seo JH; Kossenkov AV; Michalek RD; Schultz DC; Bosari S; Languino LR; Altieri DC
J Natl Cancer Inst; 2015 Mar; 107(3):. PubMed ID: 25650317
[TBL] [Abstract][Full Text] [Related]
16. Single-cell RNA sequencing reveals tumor heterogeneity, microenvironment, and drug-resistance mechanisms of recurrent glioblastoma.
Wu H; Guo C; Wang C; Xu J; Zheng S; Duan J; Li Y; Bai H; Xu Q; Ning F; Wang F; Yang Q
Cancer Sci; 2023 Jun; 114(6):2609-2621. PubMed ID: 36853018
[TBL] [Abstract][Full Text] [Related]
17. Recent advances in the use of PI3K inhibitors for glioblastoma multiforme: current preclinical and clinical development.
Zhao HF; Wang J; Shao W; Wu CP; Chen ZP; To ST; Li WP
Mol Cancer; 2017 Jun; 16(1):100. PubMed ID: 28592260
[TBL] [Abstract][Full Text] [Related]
18. Dysregulated lipid metabolism in TMZ-resistant glioblastoma: pathways, proteins, metabolites and therapeutic opportunities.
Kao TJ; Lin CL; Yang WB; Li HY; Hsu TI
Lipids Health Dis; 2023 Aug; 22(1):114. PubMed ID: 37537607
[TBL] [Abstract][Full Text] [Related]
19. Transferrin-targeted, resveratrol-loaded liposomes for the treatment of glioblastoma.
Jhaveri A; Deshpande P; Pattni B; Torchilin V
J Control Release; 2018 May; 277():89-101. PubMed ID: 29522834
[TBL] [Abstract][Full Text] [Related]
20. Development of a Function-Blocking Antibody Against Fibulin-3 as a Targeted Reagent for Glioblastoma.
Nandhu MS; Behera P; Bhaskaran V; Longo SL; Barrera-Arenas LM; Sengupta S; Rodriguez-Gil DJ; Chiocca EA; Viapiano MS
Clin Cancer Res; 2018 Feb; 24(4):821-833. PubMed ID: 29146721
[No Abstract] [Full Text] [Related]
[Next] [New Search]
